Shopping Cart 0
Cart Subtotal
AED 0

PaxVax Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

PaxVax Inc (PaxVax) is a vaccine company that develops and commercializes specialty vaccines against infectious diseases. The company develops scalable, and oral vaccines. Its activities include early-stage preclinical research and development, clinical study support, drug product manufacturing, drug substance sterile fill and finish, and packaging infrastructure. PaxVax commercializes vaccines for cholera, HIV, zika, endemic infectious diseases, chikungunya, hepatitis A, adenovirus and dengue. The company's vector vaccines are based on adenovirus serotypes 4 and 7 and the A549 cell substrate. It operates through its laboratory and manufacturing facilities located in San Diego, California; and Thorishaus, Switzerland. PaxVax is headquartered in Redwood City, California, the US.

PaxVax Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

PaxVax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

PaxVax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

PaxVax Inc, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

PaxVax Acquires Vivotif from Crucell 10

Venture Financing 11

PaxVax Raises USD12 Million in Extended Series B Financing 11

PaxVax Raises USD50 Million in Venture Debt Financing 12

PaxVax Raises USD 6 Million In Venture Financing 13

PaxVax Raises USD 22 Million In Series B Financing 14

Private Equity 15

Cerberus Capital Invests USD105 Million in PaxVax 15

Partnerships 16

PaxVax and TerahVax Korea Enter into Distribution Agreement 16

PaxVax Enters into Distribution Agreement with Seqirus 17

Valneva Enters into Distribution Agreement with PaxVax 18

PaxVax Enters into Distribution Agreement with Novartis 19

PaxVax Enters into Distribution Agreement with BioCSL 20

PaxVax Enters into Distribution Agreement with Valneva 21

Licensing Agreements 22

PaxVax Enters into Licensing Agreement with National Institutes of Health 22

PaxVax Enters into Licensing Agreement with Leukocare 23

PaxVax Enters into Licensing Agreement with University Of California, San Diego 24

Acquisition 25

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 25

PaxVax Inc-Key Competitors 27

PaxVax Inc-Key Employees 28

PaxVax Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Government and Public Interest 30

Jun 29, 2018: Same Vaccine Concept for Ebola Appears Effective Against Nipah Virus 30

Clinical Trials 31

May 04, 2018: FDA Grants PaxVax Fast Track Designation for its Chikungunya Vaccine 31

Apr 25, 2018: PaxVax Announces the Initiation of Phase 2b Trial for its Chikungunya Vaccine 32

May 08, 2017: PaxVax Initiates Clinical Trials of a Modernized Adenovirus Vaccine in Collaboration with the U.S. Army Medical Materiel Development Activity and the Walter Reed Army Institute of Research to Protect U.S. Military Personnel 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

PaxVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

PaxVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

PaxVax Inc, Pharmaceuticals & Healthcare, Key Facts 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

PaxVax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

PaxVax Inc, Deals By Therapy Area, 2012 to YTD 2018 8

PaxVax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

PaxVax Acquires Vivotif from Crucell 10

PaxVax Raises USD12 Million in Extended Series B Financing 11

PaxVax Raises USD50 Million in Venture Debt Financing 12

PaxVax Raises USD 6 Million In Venture Financing 13

PaxVax Raises USD 22 Million In Series B Financing 14

Cerberus Capital Invests USD105 Million in PaxVax 15

PaxVax and TerahVax Korea Enter into Distribution Agreement 16

PaxVax Enters into Distribution Agreement with Seqirus 17

Valneva Enters into Distribution Agreement with PaxVax 18

PaxVax Enters into Distribution Agreement with Novartis 19

PaxVax Enters into Distribution Agreement with BioCSL 20

PaxVax Enters into Distribution Agreement with Valneva 21

PaxVax Enters into Licensing Agreement with National Institutes of Health 22

PaxVax Enters into Licensing Agreement with Leukocare 23

PaxVax Enters into Licensing Agreement with University Of California, San Diego 24

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 25

PaxVax Inc, Key Competitors 27

PaxVax Inc, Key Employees 28

PaxVax Inc, Other Locations 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

PaxVax Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

PaxVax Inc (PaxVax) is a vaccine company that develops and commercializes specialty vaccines against infectious diseases. The company develops scalable, and oral vaccines. Its activities include early-stage preclinical research and development, clinical study support, drug product manufacturing, drug substance sterile fill and finish, and packaging infrastructure. PaxVax commercializes vaccines for cholera, HIV, zika, endemic infectious diseases, chikungunya, hepatitis A, adenovirus and dengue. The company's vector vaccines are based on adenovirus serotypes 4 and 7 and the A549 cell substrate. It operates through its laboratory and manufacturing facilities located in San Diego, California; and Thorishaus, Switzerland. PaxVax is headquartered in Redwood City, California, the US.

PaxVax Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

PaxVax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

PaxVax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

PaxVax Inc, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

PaxVax Acquires Vivotif from Crucell 10

Venture Financing 11

PaxVax Raises USD12 Million in Extended Series B Financing 11

PaxVax Raises USD50 Million in Venture Debt Financing 12

PaxVax Raises USD 6 Million In Venture Financing 13

PaxVax Raises USD 22 Million In Series B Financing 14

Private Equity 15

Cerberus Capital Invests USD105 Million in PaxVax 15

Partnerships 16

PaxVax and TerahVax Korea Enter into Distribution Agreement 16

PaxVax Enters into Distribution Agreement with Seqirus 17

Valneva Enters into Distribution Agreement with PaxVax 18

PaxVax Enters into Distribution Agreement with Novartis 19

PaxVax Enters into Distribution Agreement with BioCSL 20

PaxVax Enters into Distribution Agreement with Valneva 21

Licensing Agreements 22

PaxVax Enters into Licensing Agreement with National Institutes of Health 22

PaxVax Enters into Licensing Agreement with Leukocare 23

PaxVax Enters into Licensing Agreement with University Of California, San Diego 24

Acquisition 25

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 25

PaxVax Inc-Key Competitors 27

PaxVax Inc-Key Employees 28

PaxVax Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Government and Public Interest 30

Jun 29, 2018: Same Vaccine Concept for Ebola Appears Effective Against Nipah Virus 30

Clinical Trials 31

May 04, 2018: FDA Grants PaxVax Fast Track Designation for its Chikungunya Vaccine 31

Apr 25, 2018: PaxVax Announces the Initiation of Phase 2b Trial for its Chikungunya Vaccine 32

May 08, 2017: PaxVax Initiates Clinical Trials of a Modernized Adenovirus Vaccine in Collaboration with the U.S. Army Medical Materiel Development Activity and the Walter Reed Army Institute of Research to Protect U.S. Military Personnel 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

PaxVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

PaxVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

PaxVax Inc, Pharmaceuticals & Healthcare, Key Facts 2

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

PaxVax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

PaxVax Inc, Deals By Therapy Area, 2012 to YTD 2018 8

PaxVax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

PaxVax Acquires Vivotif from Crucell 10

PaxVax Raises USD12 Million in Extended Series B Financing 11

PaxVax Raises USD50 Million in Venture Debt Financing 12

PaxVax Raises USD 6 Million In Venture Financing 13

PaxVax Raises USD 22 Million In Series B Financing 14

Cerberus Capital Invests USD105 Million in PaxVax 15

PaxVax and TerahVax Korea Enter into Distribution Agreement 16

PaxVax Enters into Distribution Agreement with Seqirus 17

Valneva Enters into Distribution Agreement with PaxVax 18

PaxVax Enters into Distribution Agreement with Novartis 19

PaxVax Enters into Distribution Agreement with BioCSL 20

PaxVax Enters into Distribution Agreement with Valneva 21

PaxVax Enters into Licensing Agreement with National Institutes of Health 22

PaxVax Enters into Licensing Agreement with Leukocare 23

PaxVax Enters into Licensing Agreement with University Of California, San Diego 24

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 25

PaxVax Inc, Key Competitors 27

PaxVax Inc, Key Employees 28

PaxVax Inc, Other Locations 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

PaxVax Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.